University of California San Francisco
Give to UCSF
The repercussions of overturning Roe v. Wade – and the failure of the Supreme Court to provide any guidance on exceptions related to the life and health of the mother – are potentially catastrophic for women who face a life-threating diagnosis of pregnancy associated cancers (PAC).
A new UCSF study reports for the first time that significant hearing issues often occur among adult survivors of the most common forms of cancer.
A world-class team of researchers co-led by UCSF’s Allan Balmain, PhD, FRS, has been selected to receive a $25 million Cancer Grand Challenges award to investigate the very early stages of cancer development.
In a groundbreaking finding, a new study led by UCSF found that routine screening for and removal of precancerous anal lesions can significantly reduce the risk of anal cancer, similar to the way cervical cancer is prevented in women.
When Cheryl Broyles was diagnosed with glioblastoma, her goal was to outlive the disease’s 15-month prognosis. That was 22 years ago. Broyles’ survival has been the result of luck, tumor location, and cutting-edge treatment and diagnostics.
For many women, breast cancer screening with a three-dimensional imaging technique called digital breast tomosynthesis (DBT) may not offer advantages over digital mammography, but for some it may reduce the chance of an advanced cancer diagnosis, according to a new JAMA study.
UCSF Benioff Children’s Hospitals have been recognized among the nation’s best pediatric medical centers in all 10 specialties assessed in U.S. News & World Report's Best Children’s Hospitals 2022-23, reflecting the caliber of specialty care the hospitals provide.
A personal essay about finding joy amid the uncertainty of cancer.
A less meticulous physician might have mistaken the man’s complaints for run-of-the-mill vascular disease. Not UCSF resident Ori Lieberman.
Companies claim there’s bad stuff in our homes and bodies, and we should pay to purge it. What’s worth worrying over?
As a worldwide shortage of contrast dye for medical imaging continues, a new UCSF research letter in JAMA quantified strategies to safely reduce dye use in computed tomography (CT) by up to 83%. CT is the most common use for the dye.
UCSF research scientists and statisticians have developed improved biomarker classifications as part of their research results in the I-SPY 2 trial for high-risk breast cancer patients. The new cancer response subtypes reflect responsiveness to drug treatments and are intended to help clinicians be more precise in how they target therapies.
The latest advances in cancer care and research will be showcased at the annual American Society of Clinical Oncology (ASCO) Annual Meeting, the world’s largest clinical cancer meeting.
Eric J. Small, MD, was announced as one of the winners of the 10th annual Giants of Cancer Care® awards. Small is being recognized for his achievements in the clinical practice and research of genitourinary cancers.
Natalia Jura, an associate professor in the Department of Cellular and Molecular Pharmacology and an investigator at the UCSF Cardiovascular Research Institute, is the 27th recipient of the annual Byers Award.
Nevan Krogan, PhD, director of UCSF’s Quantitative Biosciences Institute, examines in detail the effects of a handful of genes that seem to play an outsize role in a wide array of diseases.
Wei Gordon was among nine finalists in the sixth annual UCSF Grad Slam, held March 31 – after a two-year hiatus due to the pandemic – competing to inform and entertain with three-minute talks based on their own research.
Brain tumor patients survived longer when treated aggressively with surgery, radiation and chemotherapy. Now, a UCSF study underscores the critical role of genomic profiling in diagnosing and grading brain tumors.
Leading UCSF cancer researchers will present at this year’s annual meeting of the American Association for Cancer Research conference, held April 8-13, 2022, in New Orleans, on topics such as updates on cancer’s environmental factors, targetable protein interactions, and effects on immune metabolism.
UCSF, in collaboration with the Quantum Leap Healthcare Collaborative (QLHC) and the U.S. Food and Drug Administration (FDA), has developed the OneSource system to seamlessly integrate clinical care and research data.
UCSF’s Division of Hematology-Oncology is welcoming Krishna Komanduri, MD, as division chief of Hematology-Oncology at UCSF Health. Komanduri is an international leader in the fields of hematology-oncology, transplantation, and cellular immunotherapy. He will start at UCSF on July 1.
UCSF researchers successfully leveraged an FDA-approved drug to halt growth of tumors driven by mutations in the RAS gene, which are famously difficult to treat and account for about one in four cancer deaths.
Mark Moasser, MD, has sorted out why HER2, the protein driving 1 in 5 breast cancers, is so hard to drug. He explains how the findings correct a naive way of envisioning how HER2 is shaped and how it works.
Using data from over 100,000 malignant and non-malignant cells from 15 human brain metastases, UCSF researchers have revealed two functional archetypes of metastatic cells across 7 different types of brain tumors, each containing both immune and non-immune cell types.
UCSF researchers found that cancers from different parts of the body are immunologically similar to one another. They described 12 classes of "immune archetypes" to classify cancer tumors, which can provide unique strategies for enhancing patients’ choice of cancer immunotherapies.
